950769-60-5

Basic information

• Product Name: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole
• Synonyms: 4-[2-[2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-6-yl]oxyethyl]morpholine;Imidazo[2,1-b]benzothiazole, 7-[2-(4-morpholinyl)ethoxy]-2-(4-nitrophenyl)-;7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole
• CAS NO: 950769-60-5
• Molecular Formula: C₂₁H₂₀N₄O₄S
• Molecular Weight: 424.4729
• Mol File: 950769-60-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.479g/cm³
• Refractive Index: 1.724
• CAS DataBase Reference: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(950769-60-5)
• EPA Substance Registry System: 7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole(950769-60-5)

Safety Data

• Hazardous Substances Data: 950769-60-5(Hazardous Substances Data)

Usage

General Description

7-[2-(4-Morpholinyl)ethoxy]-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole, also known as GNE-493, is a chemical compound that belongs to the class of benzothiazole derivatives. It is a potent and selective inhibitor of the checkpoint kinase 1 (Chk1), which is an important protein involved in the regulation of the cell cycle and DNA repair. GNE-493 has shown promising anti-cancer activity in preclinical studies, and it is being investigated as a potential treatment for a variety of cancers, including lung, breast, and colon cancer. Its ability to selectively target Chk1 makes it a promising candidate for combination therapies with other anti-cancer drugs. GNE-493 has the potential to improve the treatment options for cancer patients and may contribute to the development of more effective and personalized cancer therapies.

InChI:InChI=1/C21H20N4O4S/c26-25(27)16-3-1-15(2-4-16)18-14-24-19-6-5-17(13-20(19)30-21(24)22-18)29-12-9-23-7-10-28-11-8-23/h1-6,13-14H,7-12H2

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 99-81-0 4-Nitrophenacyl bromide 
• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 100-02-7 4-nitro-phenol 
• 65300-53-0 4-[2-(4-nitrophenoxy)ethyl]morpholine 
• 52481-41-1 4-(2-morpholinoethoxy)aniline 

Downstream Products

• 950769-61-6 2-(4-aminophenyl)-7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazole 
• 950769-58-1 quizartinib 
• 1132827-21-4 Quizartinib dihydrochloride 

Relevant articles and documents

Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors

As a class III receptor tyrosine kinase (RTK), FMS-like tyrosine kinase 3 (FLT3) is always overexpressed in many cases of acute leukemia. This paper studies the structure-based synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors. Encouragingly, compounds 15b, 16b, 24a, and 24c showed excellent biological activities in a low nanomolar range. In particular, compound 16b demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). It is indicated that compound 16b for the treatment of acute myeloid leukemia could be very promising.

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.